Business Wire

TX-S&B

7.3.2024 17:02:31 CET | Business Wire | Press release

Share
S&B Appoints Jeff Sipes as CEO

S&B, a leading engineering and construction firm serving the oil & gas and chemicals industries, has appointed Jeffrey G. Sipes as chief executive officer, effective immediately. Mr. Sipes has served as S&B’s chief commercial officer since 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307636885/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jeff Sipes was named Chief Executive Officer of S&B. (Photo: Business Wire)

“S&B has a remarkable record of growth and success over the past sixty years, and we look forward to decades of further success. The markets we serve are changing, creating new opportunities for growth. Jeff is the leader who can successfully guide the company to capitalize on these opportunities. He brings extensive experience and a deep understanding of both S&B’s markets and the company’s distinctive capabilities,” said J. D. Slaughter and J. W. “Brook” Brookshire, the company’s directors.

“I appreciate the confidence that the board has placed in me. S&B has unmatched strengths in many areas of the E&C market. I expect we will bring those capabilities to serving new clients as well as continuing to serve our traditional clients well,” Mr. Sipes said.

Since joining in 2021, Mr. Sipes has overseen S&B’s business development and marketing activities, including new markets and geographies, as well as the firm’s strategic planning. He led the recent strategy review that has set S&B’s future growth path.

Mr. Sipes came to S&B from Bechtel, where he served as Principal Vice President and Manager of Global Business Development focused on strategic planning, customer relationships and exploration of new global markets; he also served on Bechtel’s Operating Committee. He began his career with the engineering and construction firm Chicago Bridge & Iron Company (CB&I). Over his 30+ year career, he has served in project management, business development and leadership roles globally with extensive experience in Latin America, the Middle East and Asia. He holds a bachelor’s degree in civil engineering from Texas Tech University. In 2010, he was elected to the Texas Tech Civil Engineering Academy and served as an ambassador for the university’s International Experience Program.

Mr. Slaughter and Mr. Brookshire, who have served as S&B’s Chairman and CEO respectively, will continue as directors. They also announced that Lori Brookshire Garrison and James G. (Jimmy) Slaughter Jr. will join them on S&B’s board of directors.

About S&B

S&B is one of the leading integrated engineering, procurement, and construction firms in the United States, with more than 50 years of experience. S&B designs, builds, and delivers world-scale projects, serving energy, petrochemicals, power and public sectors, with quality, integrity and safety always at the forefront. Connect with us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240307636885/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye